Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof

ABSTRACT

The invention concerns a mixture of peptides derived from the E6 and/or E7 proteins of a papillomavirus involved in cervix of uterus cancer, such as HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57, and HPV58, for example, as well as its uses as medicine (in immunogenic compositions, capable of stimulating the production of anti-HPV T CD4+ lymphocytes in vivo and hence useful for vaccination against uterine of uterus cancer and in other cancers) or as diagnostic reagent of HPV-specific T lymphocytes, in particular for assessing the immune condition of patients. The invention also concerns a mixture of peptides derived from E6 and/or E7 proteins of a papillomavirus involved in benign skin lesions (for example warts), such as HPV10, HPV3 or HPV4 and its uses as medicine.

[0001] The present invention relates to a mixture of peptides derived from the E6 and/or E7 proteins of a papillomavirus involved in cervical cancer, such as HPV16 (papillomavirus genotype 16), HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57 and HPV58, for example, and also to uses thereof as a medicinal product (in immunogenic compositions capable of stimulating the production of anti-HPV CD4+ T lymphocytes in vivo, and therefore useful for immunization against cervical cancer and in other cancers) or as a reagent for diagnosing T lymphocytes specific for an HPV, in particular for evaluating the immune state of patients.

[0002] The present invention also relates to a mixture of peptides derived from the E6 and/or E7 proteins of a papillomavirus involved in benign lesions of the skin (warts for example), such as HPV10, HPV3 and HPV4, and to uses thereof as a medicinal product.

[0003] Human papillomaviruses (HPVs) induce benign lesions of the skin and of the mucous membranes, but are also involved in the induction of malignant lesions. They have mainly been involved in cervical cancer, which constitutes, throughout the world, the second most common cause of death from cancer in women.

[0004] They also contribute to the development of certain cancers of the penis, of the anus and of the oropharynx. The DNA of these viruses is in fact very commonly detected by PCR in biopsies from patients (1). 20 to 50% of cancers of the penis and 70% of cancers of the anus reveal the presence of HPV DNA.

[0005] There are in fact more than 100 different gentotypes of papillomavirus, each having its own pathogenicity. The association between infection with HPV and cervical cancer in fact varies according to genotypes. The low or zero malignant transformation-risk strains such as the HPV6 and HPV11 viruses are distinguished from the high-risk strains such as HPV16 and HPV18 viruses. Whatever the country, HPV16 is found in 40 to 60% of cervical cancers, whereas HPV18 is present in 10 to 20% of cases. Most of the other patients suffering from cervical cancer are infected with HPV31, HPV33 or HPV45.

[0006] For 1% of patients, no papillomavirus DNA is detected.

[0007] Experiments consisting of in vitro immortalization of keratinocytes with HPV DNA have revealed that two genes (E6 and E7) are mainly responsible for the cell transformation. In these experiments, the DNA derived from high-risk viral strains is capable of transforming the cells, whereas the low-risk strains are not capable of doing this. The E6 protein binds to p53, which has tumor-suppressing activity, and induces its degradation. The E7 protein binds to the pRb protein, which also has tumor-suppressing activity. These activities are higher for the E6 and E7 proteins of high-risk strains than for the low-risk strains. In addition, the pRb and p53 genes are mutated and inactive in cervical cell lines which are not infected with HPV, whereas this is not the case in infected lines. All of these observations strongly suggest that the E6 and E7 proteins are key components of HPV infection and of the induction of cancerous states.

[0008] In the absence of antiviral treatments specific for HPV infections, the development of anti-HPV vaccines constitutes one of the promising approaches for combating the forms of cancer induced by these viruses.

[0009] The use of attenuated or inactivated forms of viruses is, however, difficult to apply due, firstly, to the current lack of means for producing the virus and, secondly, to the presence in its genome of transforming genes.

[0010] An approach based on peptides or subunits therefore appears to be very advantageous. In particular, it is known that suitably chosen peptides are capable of recruiting both cytotoxic T lymphocytes (CTLs) and helper Tlymphocytes of the Th1 type directed specifically against the transformed cells.

[0011] In this context, the E6 and E7 proteins constitute preferred targets since they contribute directly to the cancerization of cells, and their early expression after infection persists in the transformed cell.

[0012] Various immunization strategies using peptides derived from these two proteins have thus been recommended.

[0013] These strategies are based on the fact that CD4+ T lymphocytes play a major role in establishing the immune responses and in particular of the CTLs. Recent studies have shown that they are involved, via CD40 molecules, in the activation of dendritic antigen-presenting cells which are required for stimulation of the specific CTLs (J. P. Ridge et al., Nature, 1998, 393, 474; S. P. Schoenberger et al., Nature, 1998, 393, 480; S, R. Bennett et al., Nature, 1998, 393, 478; R. E M. Toes et al., Semin. Immunol., 1998, 10, 443).

[0014] The activation of the CD4+ T lymphocytes takes place through the presentation of the viral peptides by the HLA II molecules carried by the antigen-presenting cells (APCs). These peptides, called T epitopes, result from the proteolytic degradation of the viral antigens by the APC. They are variable in length, generally from 13 to 25 amino acids, and have a sequence which makes them capable of binding to the HLA II molecules.

[0015] It is now established that a peptide, T epitope, is capable, to the same extent as the native antigen, of stimulating, in vitro, CD4+ T lymphocytes which are specific for it, or of recruiting them in vivo.

[0016] T epitopes are therefore sufficient to induce a CD4+ response. However, one of the major problems which limits the use of these peptides is that their sequence varies from one individual to another, due to the polymorphism of HLA II molecules, which are heterodimers expressed on the antigen-presenting cells (APCs) and which present to the CD4+ T lymphocytes the T epitopes of said antigens. These molecules are capable of binding a considerable repertoire of peptides having very different sequences, which allows them to present to the T cells several peptides per antigen.

[0017] Four different types of HLA II molecule exist per individual: 2 HLA-DR, 1 HLA-DQ and 1 HLA-DP; the HLA-DR molecule, the β-chain of which is encoded by the DRB1 gene (1st gene), is the most highly expressed. There are currently listed more than 200 different alleles for DRB1, which define various antigens or types, as summarized in table I below. TABLE 1 Molecules expressed by various HLA-DRB1 alleles Antigen Allele Alias DR1 DRB1*0101 DR1 DR3 DRB1*0301 DR3w17 DR4 DRB1*0401 DR4w4 DRB1*0405 DR4w15 DR7 DRB1*0701 DR7 DR8 DRB1*0802 DR8w2 DR9 DRB1*0901 DR9 DR11 DRB1*1101 DR5w11 DR12 DRB1*1201 DR5w12 DR13 DRB1*1301 DRB1*1302 DR6w19 DR15 DRB1*1501 DR2w2b

[0018] Each allele has its own binding properties; the wide specificity of the HLA II molecules and the existence of several isoforms and of a polymorphism mean that each individual recognizes, in an antigen, a set of peptides the nature of which depends on the HLA II molecules which characterize it. Since a large number of HLA II alleles exist, a large number of T epitopes, specific for each allele, therefore exist for a given antigen.

[0019] In addition, the distribution of the alleles in a given population is not homogeneous: for example, in the French population, which corresponds to a mainly Caucasian population, only 7 alleles of the DRB1 locus exceed 5%; these are the alleles: DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301 and DRB1*1501, which represent 64% of the population (4). These same alleles are also in the majority in other European populations, where their frequency ranges from 53% (Spain) to 82% (Denmark), and also in North America (55-58%).

[0020] The HLA-DRB3, -DRB4 and -DRB5 molecules (2nd gene), which are HLA-DR molecules wherein the β-chain is not encoded by the DRB1 gene, are also present with high allelic frequencies in the various Caucasian populations: 9.2% for DRB3*0101 (B3), 28.4% for DRB4*0101 (B4) and 7.9% for DRB5*0101 (B5). They therefore cover, by themselves, 45% of the allelic frequency in Caucasian populations.

[0021] The peptides present in a peptide sequence and which bind all these alleles include the T epitopes of the majority of the Caucasian population.

[0022] One of the most commonly used means for defining helper CD4+ T epitopes is to measure the ability of the peptides to cause proliferation of the mononuclear cells of individuals having been in contact with the antigen under consideration.

[0023] A certain number of documents propose a selection of epitopes derived from the E6 or E7 proteins of HPV16, which can be used to produce a vaccine:

[0024] International application WO 00/14244 (Connaught Laboratories Ltd) recommends, to obtain a specific immunity without producing any risks of oncogenic transformation, the use of constructs (vectors) wherein a certain number of T epitopes derived both from E6 and from E7 are linked together. More precisely, the antigens can be in the form of whole proteins or of T epitopes. For example, the T epitope of the E6 protein is preferably the epitope corresponding to positions 29-38 of said protein and the preferred epitopes of the E7 protein are those corresponding respectively to positions: 11-20, 49-57, 82-90, 86-93; the use of an E7 protein detoxified by deletion of the Rb protein-binding site is also envisioned.

[0025] Application EP 0 451 550 (Behringwerke) describes seroactive epitopes and in particular epitopes derived from the E6 protein or from the E7 protein of HPV16, and also a vaccine containing one or more of said epitopes.

[0026] Patent EP 0 561 885 (University of Queensland and CSL Ltd) describes a subunit vaccine against the HPV16 papillomavirus, which comprises the sequence DRAHYNI of the E7 protein (positions 48-54), considered to induce an immune response significantly greater than other epitopes.

[0027] Patent application 0 386 734 (Behringwerke) describes two dominant immunogenic regions in the E7 protein of HPV16, corresponding respectively to positions 12-27 and 36-52, and their use in reagents for detection.

[0028] Luxton et al. have emphasized the importance of cellular immunity in the control of genital infections with HPV and have, consequently, studied the proliferative T response to HPV infections; insofar as immunization of mice with peptides derived from the E6 and E7 proteins of HPV16 protects against a virulent challenge consisting of HPV16-transformed cancerous cells, they have in particular shown the advantage of the E7 protein of HPV16 and have sought to identify T epitopes in this protein. To do this, they have produced synthetic peptides of 15 amino acids, the sequence of which overlaps by 5 amino acids, so as to obtain a series of peptides representing the entire sequence of the E7 protein. They have shown that the proliferative T response depends on the state of the patient and that, in asymptomatic individuals, the peptides located in the N- and C-terminal regions (peptides 1-34 and 70-98) induce an immunological response, whereas this is not the case in the patients exhibiting cervical dysplasia. They have mainly shown that the E7 peptide 80-94 of the HPV16 genotype causes the cells of 6 individuals out of the 7 tested to proliferate (J. Gen. Virol., 1996, 77, 1585) (see table II below).

[0029] G. Strang et al. have defined four T epitopes of HPV16, one of which is present in E6 (J. Gen. Virol., 1990, 71, 423).

[0030] A. Altmann et al. have isolated E7-specific T lymphocyte lines from two patients and characterized the peptides recognized (Eur. J. Cancer, 1992, 28, 326). The study was carried out with synthetic peptides of 14 amino acids, the sequence of which overlaps by 10 amino acids, so as to obtain a series of peptides representing the entire sequence of the E7 protein.

[0031] T. Tsukui et al. has studied the secretion of IL2 by cells in the blood, in 140 HPV16+ patients having various stages of lesion (Cancer Res., 1996, 56, 3967).

[0032] M. Nakagawa et al. have mainly observed that peptide 24-45 of E6 of the HPV16 genotype causes proliferation of the cells of 13 individuals out of 63 tested (Immunol., 1996, 3, 205). They have also studied the responses observed with the E7 protein and has shown that little response is observed with this protein.

[0033] A. S. Kadish et al. has studied the proliferative response of the cells of HPV16+ patients to E6 and E7 peptides (Cancer Inst., 1997, 89, 1285).

[0034] T. D. de Gruijl et al. have studied the proliferation of cells from patients infected with HPV and have observed that, among the peptides covering the sequence of the E7 protein of the HPV16 virus, peptide 67-98 stimulates the cells of a majority of patients (Cancer Res., 1998, 58, 1700).

[0035] All the E6 and E7 sequences identified as being T epitopes in the patients studied are illustrated in table II. TABLE II HPV16 peptides Documents (positions) Properties WO 00/14244 E6: 29-38 E7: 11-20, 49-57, 82-90, 86-93 EP 0 451 550 E6: 7-37 E7: 6-26, 9-19, 7-21, 10-23, 36-52, 40-54 EP 0 561 885 E7: 48-54, 44-54, 44-62, 44-57, 44-56, 44-60, 44-48, 38-41, 10-14, 11-14 EP 0 375 555 E7: 45-58 EP 0 386 734 E7: 12-27, 12-23, 12-20, 12-19 and 36-52 Strang E6: 42-57 Recognized by DR7-restricted et al. (14) clone Altmann E7: 5-18 Recognized by line from a DR1 et al. (15) DR11 patient E7: 17-34 Recognized by line from a DR4 DR13 patient E7: 69-82 Recognized by clone from a DR4 DR13 patient Tsukui Secretion of IL2 (activation of et al. (17) cells) by patients E6: 1-45  0/140 E6: 59-112  6/140 E6: 111-158 11/140 E7: 1-35  3/140 E7: 27-60  4/140 E7: 51-98  7/140 Luxton Proliferation of cells from et al. (16) patients (CIN or normal) E7: 1-14  0/31 CIN and 1/15 normal E7: 10-24  0/31 CIN and 3/15 normal E7: 20-34  0/31 CIN and 0/15 normal E7: 25-49  3/31 CIN E7: 30-44  2/31 normal E7: 40-54  0 CIN and 0 normal E7: 45-64  2/31 CIN and 1/15 normal E7: 55-74  2/31 CIN and 1/15 normal E7: 70-98  4/31 CIN and 7/15 normal Nakagawa Proliferation of cells from et al. (18) patients (CIN or normal) E6: 4-29  3/22 CIN and 12/65 normal E6: 24-45  1/22 CIN and 15/65 normal E6: 109-122  1/22 CIN and 8/65 normal E7: 21-30  0/22 CIN and 5/65 normal E7: 44-57  3/22 CIN and 9/65 normal E7: 62-79  3/22 CIN and 10/65 normal Kadish Proliferation of cells from et al. (19) patients (CIN or normal) E6: 1-31 17/48 E6: 22-51 17/46 E6: 42-71  8/43 E6: 62-91  0/30 E6: 82-111  5/34 E6: 102-131 14/43 E6: 122-151 19/48 E6: 142-159 17/49 E6: 17-31 12/23 E6: 117-131 12/23 E6: 137-151  9/23 E7: 62-80 11/35 E7: 72-97 19/48 De Gruijl E7: 1-32  8/28 et al. (20) E7: 19-56 10/28 E7: 43-80 10/28 E7: 67-98 17/28

[0036] Considerable differences are observed between the studies, reflecting the relative imprecision of this approach. It is in fact difficult, in view of the diversity of the responses observed, to define T epitope sequences for the entire population. These sequences are adapted only to the patients involved in these studies. These differences in response can be explained, firstly, by the representativeness of the samples, which is not evaluated. In particular, in the studies where the patients are not typed for their HLA molecules, no one knows whether the various alleles are represented according to the frequencies in the general population. A response, common to many patients, to a particular peptide may therefore result from a bias in the sampling and not from the effective ability of a peptide to be recognized by all the patients. Furthermore, in the case of infection with HPV, the persistence of the antigen may induce a state of immune tolerance against the T epitopes of the virus, those best recognized by the T cells, as has been shown in a mouse model transgenic for the E7 protein of HPV (T. Doan et al., J. Virol., 1999, 73, 6166). In this respect, it may be noted that the response is often weaker in the patients who have eliminated the virus compared to the infected patients (T. Tsukui et al., 1996, mentioned above). In this context, the most advantageous epitopes might have disappeared from the immune response, which would be maintained for less stimulatory determinants but which would not succeed in eliminating the virus.

[0037] These proliferation assays are therefore insufficient to define sequences suitable for the entire population.

[0038] Thus, it emerges from the various studies that the peptides that helper T lymphocytes recognize are difficult to define due to the polymorphism of the HLA II molecules.

[0039] In addition, to date, immunization trials in women to induce anti-HPV immunity have not made it possible to obtain clinically satisfactory results. Eight patients suffering from cervical cancer were immunized with a dose of vaccinia virus recombined with the genes encoding the E6 and E7 proteins (L. K. Borysiewicz et al., Lancet., 1996, 347, 1523). A cytotoxic response was detected only transiently and in only one patient.

[0040] The results obtained with peptides have also not been very conclusive, with zero clinical effectiveness. M. E. Ressing et al. (J. Immunother., 2000, 23, 255) and W. J. Van Driel et al. (Eur. J. Cancer, 1999, 35, 946) have used a combination of two HPV peptides and a helper peptide which is universal but not specific for the virus. No cytotoxic response was induced. It is probable that the lack of response is due to the inability of the constructs to induce stimulation of both the HPV-specific helper CD4+ T lymphocytes and the CD8+ lymphocytes.

[0041] Consequently, all the peptides proposed to date correspond to T epitopes, which are specific only for particular individuals; in fact, an inter-individual variability in T epitopes exists which makes it difficult to choose molecules suitable for mass immunization against HPV16; consequently, the peptides described above are not suitable for the preparation of an immunogenic and immunizing composition capable of stimulating anti-HPV16 CD4+ T lymphocytes and generating a protective immune response, regardless of the individual to be protected, since they do not stimulate a protective CD4+ T response in all the individuals to be treated.

[0042] For this reason, the inventors gave themselves the aim of providing a set of peptides capable of being incorporated into an immunogenic composition and of stimulating anti-HPV CD4+ T lymphocytes, in the majority of European or North American Caucasian individuals, so as to effectively induce a specific proliferative response against components of the virus.

[0043] Such a set has the property of being effective in a large number of individuals, whereas the peptides of the prior art are active in some individuals and are inactive in most of the other individuals, because the latter do not recognize the E6 and E7 proteins of HPV16 via the same determinants.

[0044] To do this, the inventors have selected peptides derived from the E6 and E7 proteins of one of the abovementioned HPVs, in particular of HPV16, restricted with respect to the HLA II molecules predominant in Caucasian populations, and have found that, in combination, the peptides selected effectively induce an immunogenic and protective response in a large number of individuals.

[0045] Consequently, a subject of the present invention is a mixture of peptides derived from an E6 protein and/or from an E7 protein of an HPV involved in cervical cancer or benign lesions of the skin, characterized in that each of the peptides included in said mixture binds to at least one HLA-DRB1 (1st gene) molecule the frequency of which is greater than 5% in the Caucasian population and, optionally, to at least one HLA-DRB3, HLA-DRB4 or HLA-DRB5 (2nd gene) molecule, with a binding activity <1 000 nM, preferably <800 nM, said mixture of peptides binding at least eight HLA class II molecules, the frequency of which is greater than 5% in the Caucasian population, encoded by the alleles selected from the group consisting of the alleles HLA DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301 and DRB1*1501 (DR1, DR3, DR4, DR7, DR11, DR13 and DR15 molecules) (1st gene) and the alleles DRB3*0101, DRB4*0101 and DRB5*0101 (B3, B4 and B5) (2nd gene).

[0046] Such a mixture of peptides makes it possible to obtain, surprisingly, a proliferative CD4+ T response (stimulation of CD4+ T lymphocytes) and also stimulation of the CTL response, in a great majority of the Caucasian population to be protected and whatever the HPV concerned; it may therefore be considered that such a mixture constitutes a first step toward a “universal” immunogenic composition which can be used in a vaccine.

[0047] According to an advantageous embodiment of said mixture, the peptides derived from an E6 protein of HPV are derived from HPV16 and are selected from the group consisting of:

[0048] (a) a peptide included between positions 14 and 16, selected from the group consisting of the peptide corresponding to positions 14-34 and the peptide corresponding to positions 14-46 (SEQ ID Nos. 8, 19),

[0049] (b) the peptide corresponding to positions 30-50 (SEQ ID No. 10),

[0050] (c) a peptide included between positions 44 and 67, selected from the group consisting of the peptide corresponding to positions 45-67 and the peptide corresponding to positions 44-67 (SEQ ID Nos. 26, 27),

[0051] (d) the peptide corresponding to positions 61-80 (SEQ ID No. 11),

[0052] (e) a peptide included between positions 76 and 119, selected from the group consisting of the peptide corresponding to positions 76-95, the peptide corresponding to positions 91-110 and the peptide corresponding to positions 91-119 (SEQ ID Nos. 12, 35, 13),

[0053] (f) a peptide included between positions 118-140, selected from the group consisting of the peptide corresponding to positions 118-140 and the peptide corresponding to positions 121-140 (SEQ ID Nos. 40, 41),

[0054] (g) the peptide corresponding to positions 135-158 (SEQ ID No. 44), of the E6 protein of HPV16, and

[0055] (h) the peptides, preferably of 15 to 20 amino acids, exhibiting an amino acid sequence having at least 60% identity or at least 80% similarity, and preferably at least 70% identity or at least 99% similarity, with the peptides defined in (a)-(g), said peptides being identical in size, or included in the peptides defined in (a)-(g) or else completely or partially overlapping these peptides, with the exclusion of the peptides corresponding to positions 15-44, 46-67, 80-108 and 118-139 (SEQ ID Nos. 53-56) of the E6 protein of HPV16.

[0056] The identity of a sequence with respect to a reference sequence is assessed as a function of the percentage of amino acid residues which are identical, when the two sequences are aligned so that they correspond to one another to a maximum.

[0057] A peptide having an amino acid sequence having at least X % identity with a reference sequence comprising Y amino acids is defined, in the present invention, as a peptide the sequence of which can include up to Y-X′ alterations per Y amino acids of the reference sequence and reformulated for a sequence of 100 amino acids.

[0058] The similarity of a sequence with respect to a reference sequence is assessed as a function of the percentage of amino acid residues which are identical or which differ by conservative substitutions, when these two sequences are aligned so that they correspond to one another to a maximum. For the purpose of the present invention, the term “conservative substitution” is intended to mean the substitution of an amino acid with another which exhibits similar chemical properties (size, charge or polarity), which generally does not modify the functional properties of the peptide.

[0059] Advantageously, the peptides derived from an E6 protein of HPV of said mixture, as defined in (h), are selected from the group consisting of:

[0060] the peptides of 15 amino acids included in the peptide corresponding to positions 14-34 or overlapping this peptide, chosen from the peptides corresponding respectively to positions 20-34, 24-38 and 28-42 (SEQ ID Nos. 21-23),

[0061] the peptides of 15 amino acids included in the peptide corresponding to positions 30-50 or overlapping this peptide, chosen from the peptides corresponding respectively to positions 31-45 and 36-50 (SEQ ID Nos. 24-25);

[0062] the peptides of 15 amino acids included in the peptide corresponding to positions 45-67 or overlapping this peptide, chosen from the peptides corresponding respectively to positions 42-56, 50-64 and 55-69 (SEQ ID Nos. 28-30);

[0063] the peptides of 15 to 17 amino acids included in the peptide corresponding to positions 76-95 or overlapping this peptide, chosen from the peptides corresponding respectively to positions 76-90, 78-92, 81-95 and 84-98 (SEQ ID Nos. 31-34);

[0064] the peptides of 15 amino acids included in the peptide corresponding to positions 91-110 or overlapping this peptide, chosen from the peptides corresponding, respectively, to positions 89-103, 93-107, 97-111 and 101-115 (SEQ ID Nos. 36-39);

[0065] the peptides of 15 amino acids included in the peptide corresponding to positions 121-140 or overlapping this peptide, chosen from the peptides corresponding respectively to positions 124-138 and 130-144 (SEQ ID Nos. 42-43).

[0066] According to another advantageous embodiment of said mixture, the peptides derived from an E7 protein are derived from HPV16 and are selected from the group consisting of the peptide corresponding to positions 1-20, the peptide corresponding to positions 7-27, the peptide corresponding to positions 65-87 and the peptide corresponding to positions 78-98 of said E7 protein of HPV16 (SEQ ID Nos. 14, 15, 17, 18) and the peptides, preferably of 15 to 20 amino acids, exhibiting an amino acid sequence having at least 60% identity or at least 80% similarity, and preferably at least 70% identity or at least 99% similarity, with the peptides as defined above, said peptides being identical in size, or included in the peptides as defined above or else overlapping these peptides, with the exclusion of the peptides corresponding to positions 3-25 and 79-97 of the E7 protein of HPV16 (SEQ ID Nos. 57, 58).

[0067] Advantageously, the peptides derived from an E7 protein of said mixture, included in the peptides (SEQ ID Nos. 14, 15, 17, 18) as defined above or else overlapping these peptides, are selected from the group consisting of the peptides corresponding respectively to positions 6-20, 9-23, 13-27, 65-79, 67-81, 72-86, 77-91 and 84-98 of the E7 protein of HPV16 (SEQ ID Nos. 45-52).

[0068] Particularly advantageously, said mixture of peptides according to the invention is selected from the group consisting of the following mixtures:

[0069] a mixture of peptides derived from the E6 protein of HPV16, comprising: the peptide corresponding to positions 14-34 or to positions 14-46, the peptide corresponding to positions 30-50 and the peptide corresponding to positions 44-67 or to positions 45-67;

[0070] a mixture of peptides derived from the E6 protein of HPV16, comprising: the peptide corresponding to positions 61-80, the peptide corresponding to positions 76-95 and the peptide corresponding to positions 91-119;

[0071] a mixture of peptides derived from the E7 protein of HPV16, comprising: the peptide corresponding to positions 1-20 and the peptide corresponding to positions 7-27;

[0072] a mixture of peptides derived from the E7 protein of HPV16, comprising: the peptide corresponding to positions 65-87 and the peptide corresponding to positions 78-98;

[0073] and the mixtures comprising one of the mixtures of peptides derived from the E6 protein HPV16 and one of the mixtures derived from the E7 protein of HPV16, as defined above.

[0074] Specifically:

[0075] the peptide E6 (14-34) binds with good affinity to the DRB1*0301, 0701 and 1501 molecules,

[0076] the peptide E6 (30-50) binds with good affinity to the DRB1*0101, 0301, 0401, 1101, 1301 and 1501, DRB5*0101 and DRB4*0101 molecules,

[0077] the peptide E6 (61-80) binds with good affinity to the DRB1*0301, 1101 and 1501, DRB3*0101 and DRB5*0101 molecules,

[0078] the peptide E6 (76-95) binds with good affinity to the DRB1*0101, 1101, 1301 and 1501, DRB5*0101 and DRB4*0101 molecules,

[0079] the peptide E6 (91-119) binds with good affinity to the DRB1*0101, 0301, 0401, 0701 and 1501 and DRB5*0101 molecules,

[0080] the peptide E7 (1-20) binds with good affinity to the DRB1*0101, 0301, 0401, 1101, 1301 and 1501, DRB5*0101 and DRB4*0101 molecules,

[0081] the peptide E7 (7-27) binds with good affinity to the DRB1*0101, 0301, 0401, 1101 and 1301, DRB3*0101, DRB5*0101 and DRB4*0101 molecules,

[0082] the peptide E7 (60-74) binds with good affinity to the DRB1*0701 and DRB5*0101 molecules,

[0083] the peptide E7 (65-87) binds with good affinity to the DRB1*0101, 0301, 0401, 0701 and 1501 and DRB3*0101 molecules,

[0084] the peptide E7 (78-98) binds with good affinity to the DRB1*0101, 0701, 1101 and 1501, DRB5*0101 and DRB4*0101 molecules.

[0085] The sequences of these various peptides are given in tables III and IV below: TABLE III Identification Peptide Sequence number E6(1-22) MHQKRTAMFQDPQERPRKLPQL SEQ ID No. 59 E6(14-34) ERPRKLPQLCTELQTTIHDII SEQ ID No. 8 E6(30-50) IHDIILECVYCKQQLLRREVY SEQ ID No. 10 E6(45-67) LRREVYDFAFRDLCIVYRDGNPY SEQ ID No. 26 E6(61-80) YRDGNPYAVCDKCLKFYSKI SEQ ID No. 11 E6(76-95) FYSKISEYRHYCYSLYGTTL SEQ ID No. 12 E6(91-110) YGTTLEQQYNKPLCDLLIRC SEQ ID No. 35 E6(105-126) DLLIRCINCQKPLCPEEKQRHL SEQ ID No. 60 E6(121-140) EKQRHLDKKQRFHNIRGRWT SEQ ID No. 41 E6(135-158) IRGRWTGRCMSCCRSSRTRRETQL SEQ ID No. 44 E7(1-20) MHGDTPTLHEYMLDLQPETT SEQ ID No. 14 E7(7-27) TLHEYMLDLQPETTDLYCYEQ SEQ ID No. 15 E7(21-40) DLYCYEQLNDSSEEEDEIDG SEQ ID No. 61 E7(35-55) EDEIDGPAGQAEPDRAHYNIV SEQ ID No. 62 E7(43-57) GQAEPDRAHYNIVTF SEQ ID No. 63 E7(60-74) KCDSTLRLCVQSTHV SEQ ID No. 16 E7(65-87) LRLCVQSTHVDIRTLEDLLMGTL SEQ ID No. 17 E7(78-98) TLEDLLMGTLGIVCPICSQKP SEQ ID No. 18

[0086] TABLE IV Peptide Sequence E6/2 (14-34) E R P R K L P Q L C T E L Q T T I H D I I E6/17-31    R K L P Q L C T E L Q T T I H E6/20-34       P Q L C T E L Q T T I H D I I E6/24-38           T E L Q T T I H D I I L E C V E6/28-42               T T I H D I I L E C V Y C K Q E6/3 (30-50) I H D I I L E C V Y C K Q Q L L R R E V Y E6/31-45  H D I I L E C V Y C K Q Q L L E6/36-50       E C V Y C K Q Q L L R R E V Y E6/4 (45-67)     L R R E V Y D F A F R D L C I V Y R D G N P Y E6/42-56  Q Q L L R R E V Y D F A F R D E6/50-64          Y D F A F R D L C I V Y R D G E6/55-69               R D L C I V Y R D G N P Y A V E6/6 (76-95) F Y S K I S E Y R H Y C Y S L Y G T T L E6/76-90      F Y S K I S E Y R H Y C Y S L E6/78-92        S K I S E Y R H Y C Y S L Y G E6/81-95           S E Y R H Y C Y S L Y G T T L E6/84-98              R H Y C Y S L Y G T T L E Q Q E6/7 (91-110)     Y G T T L E Q Q Y N K P L C D L L I R C E6/89-103   S L Y G T T L E Q Q Y N K P L E6/93-107       T T L E Q Q Y N K P L C D L L E6/97-111           Q Q Y N K P L C D L L I R C I E6/101-115               K P L C D L L I R C I N C Q K E6/9 (121-140) E K Q R H L D K K Q R F H N I R G R W T E6/124-138     H L D K K Q R F H N I R G R E6/130-144          Q R F H N I R G R W T G R C M E7/1 (1-20) M H G D T P T L H E Y M L D L Q P E T T E7/6-20      P T L H E Y M L D L Q P E T T E7/2 (7-27) T L H E Y M L D L Q P E T T D L Y C Y E Q E7/9-23   H E Y M L D L Q P E T T D L Y E7/13-27       L D L Q P E T T D L Y C Y E Q E7/7 (65-87) L R L C V Q S T H V D I R T L E D L L M G T L E7/65-79 L R L C V Q S T H V D I R T L E7/67-81   L C V Q S T H V D I R T L E D E7/72-86        T H V D I R T L E D L L M G T E7/8 (78-98)  T L E D L L M G T L G I V C P I C S Q K P E7/77-91 R T L E D L L M G T L G I V C E7/84-98        M G T L G I V C P I C S Q K P

[0087] Other peptides exhibit binding activities, but on a limited number of molecules.

[0088] A subject of the present invention is also an immunogenic anti-HPV composition, characterized in that it comprises a mixture of peptides derived from an E6 protein of HPV and/or a mixture of peptides derived from an E7 protein of HPV, as defined above, combined with at least one pharmaceutically acceptable vehicle and, optionally, with at least one adjuvant.

[0089] The adjuvants used are adjuvants conventionally used in vaccine compositions, such as alumina hydroxide and squalene.

[0090] According to advantageous embodiment of said immunogenic composition, said peptides are either in the form of lipopeptides, or incorporated into a recombinant virus, a viral vector for gene therapy (adenovirus, etc.), or included in a protein and in particular a recombinant protein (Leclerc C. et al., Int. Rev. Immunol., 1994, 11, 2, 123-132; Janssen R. et al., Int. Rev. Immunol., 1994, 11, 2, 113-121), or chemically modified. In the latter case, they comprise, for example, unnatural modifications such as D amino acids, pseudopeptide bonds or modifications of the C- or N-terminal ends.

[0091] The lipid moiety of the lipopeptide is in particular obtained by addition of a lipid unit to an a-amino function of said peptides or to a reactive function of the side chain of an amino acid of the peptide moiety; it may comprise one or more optionally branched or unsaturated C₄-C₂₀ fatty acid-derived chains (palmitic acid, oleic acid, linoleic acid, linolenic acid, 2-aminohexadecanoic acid, pimelautide, trimetauxide) or a derivative of a steroid. The method for preparing such lipopeptides is in particular described in international applications WO 99/40113 and WO 99/51630. The preferred lipid moiety is in particular represented by an N^(α)-acetyl-lysine N^(ε)(palmitoyl) group, also referred to as Ac-K(Pam).

[0092] According to another advantageous embodiment of said immunogenic composition, said mixture of peptides is combined:

[0093] with one or more peptides or lipopeptides containing one or more CD8+ epitopes (specifically recognized by cytotoxic T lymphocytes and presented by HLA I molecules), and more particularly the CD8+ epitopes derived from an HPV protein, in particular from an HPV16 protein (Ressing et al., van Driel et al.) and/or

[0094] with other peptides comprising multiple CD4+ epitopes, such as the tetanus toxin TT peptide (positions 830-846), the Influenza hemagglutinin HA peptide (positions 307-319), PADRE (Pan DR Epitope, Alexandre J. et al., Immunity, 1994, 1, 9, 751-761) or the Plasmodium falciparum LSA3 peptide and/or

[0095] with one or more peptides or lipopeptides containing one or more B epitopes, more particularly B epitopes derived from an HPV16 protein (Tindle et al.), specifically recognized by antibodies directed against these epitopes.

[0096] The E6 and E7 peptides according to the invention, included in the mixtures, as defined above were advantageously selected using an HLA-DR/peptide binding assay comprising:

[0097] purifying the HLA-DR molecules of interest, i.e. those involving more than 5% of a given population, and in particular the HLA DR1, DR3, DR4, DR7, DR11, DR13 and DR15 molecules,

[0098] incubating the HLA-DR molecules thus purified with various concentrations of overlapping fragments entirely covering the sequence of the E6 protein or of the E7 protein and with a reagent R1 or tracer consisting of a peptide fragment associated with a nonradioactive label, such as biotin, and the sequence of which is different from said peptides; the reagent R1 or tracer is chosen in such a way that it exhibits an affinity with respect to one of the HLA-DR molecules of interest, such that it may be used at a concentration <200 nM,

[0099] transferring the complexes obtained onto an ELISA-type plate precoated with an antibody specific for all the HLA-DRs,

[0100] revealing the HLA-DR molecule/reagent R1 complexes attached to the bottom of the plate by means of suitable conjugates, such as streptavidin-phosphatase, and of a fluorescent substrate,

[0101] selecting the peptides comprising different epitopes, i.e. the most representative of the various regions of interaction between the E6 protein or the E7 protein and the HLA-DR molecules, and

[0102] choosing the most suitable peptides, as a function of the frequency of the alleles with respect to which they exhibit a binding activity <1 000 nM, preferably <800 nM, corresponding to the concentration of these peptides which inhibits 50% of the binding of the reagent R1 (IC₅₀).

[0103] These assays make it possible to unambiguously associate with each allele of the 1st gene or of the 2nd gene the sequences of the fragments capable of binding thereto or, on the contrary, which do not bind thereto.

[0104] This approach makes it possible to define immunogenic compositions including peptides which bind to the greatest number of different HLA-DR molecules and which may thus be advantageously protective for the majority of patients, even if their HLA molecules are not known.

[0105] This approach also has the advantage of making it possible to select peptides which are significantly more specific with respect to HPV16 than the approaches seeking to select peptides on the basis of their ability to stimulate CD4+ T lymphocytes (proliferation assays).

[0106] The incubation conditions are specific to each HLA-DR molecule (incubation time, pH, reagent R1, concentration of HLA-DR or of peptide).

[0107] The reagent R1 is selected from the group consisting of the following sequences:

[0108] PKYVKQNTLKLAT (HA 306-318) (SEQ ID No. 1), specific for the alleles DRB1*0101, DRB1*0401, DRB1*1101,

[0109] EAEQLRAYLDGTGVE (A3 152-166) (SEQ ID No. 2), specific for the allele DRB1*1501,

[0110] AKTIAYDEEARGLE (MT 2-16) (SEQ ID No. 3), specific for the allele DRB1*0301,

[0111] AAYAAAKAAALAA (YKL) (SEQ ID No. 4), specific for the allele DRB1*0701,

[0112] TERVRLVTRHIYNREE (B1 21-36) (SEQ ID No. 5), specific for the allele DRB1*1301,

[0113] ESWGAVWRIDTPDKLTGPFT (LOL 191-210) (SEQ ID No. 6), specific for the allele DRB3*0101, and

[0114] AGDLLAIETDKATI (E2/E168) (SEQ ID No. 7), specific for the allele DRB4*0101.

[0115] Other reagents R1 can be used, in particular those described in Southwood et al. (24).

[0116] As a variant, said immunogenic composition advantageously comprises the sequences encoding the peptides as defined above.

[0117] In fact, the use of naked DNA for immunization constitutes an effective vaccinal approach: it consists in injecting into the host organism to be vaccinated a naked DNA encoding a protein antigen; this DNA allows sustained synthesis of the antigen by the host's cells and also long-lasting presentation of this antigen to the immune system.

[0118] A subject of the present invention is also a vaccine, characterized in that it includes an immunogenic composition as defined above.

[0119] A subject of the present invention is also peptides derived from an E6 protein of HPV, in particular of HPV16, and/or from an E7 protein of HPV, in particular of HPV16, characterized:

[0120] in that they contain a CD4+ epitope capable of having a binding activity <1 000 nM, preferably <800 nM with respect to at least one HLA II (HLA-DR) molecule predominant in Caucasian populations (1st gene and/or 2nd gene), as defined above, of being recognized by CD4+ T lymphocytes specific for said peptides, and of stimulating CD4+ T lymphocytes specific for said peptides, and

[0121] in that they are selected from the group consisting of the fragments of sequence SEQ ID Nos. 8 to 18, 21-25, 28-34, 36-39, 42-43 and 45-52, corresponding respectively to the following peptides of the E6 protein of HPV16: the peptide E6 (14-34 or 14-45), the peptide E6 (30-50), the peptide E6 (61-80), the peptide E6 (76-95), the peptide E6 (91-119) and the peptides E6 (20-34, 24-38, 28-42, 31-45, 36-50, 42-56, 50-64, 55-69, 76-90, 78-92, 81-95, 84-98, 89-103, 93-107, 97-111, 101-115, 124-138, 130-144), or to the following peptides of the E7 protein of HPV16: the peptide E7 (1-20), the peptide E7 (7-27), the peptide E7 (60-74), the peptide E7 (65-87), the peptide E7 (78-98) and the peptides E7 (6-20, 9-23, 13-27, 65-79, 67-81, 72-86, 77-91, 84-98).

[0122] A subject of the present invention is a diagnostic reagent, characterized in that it is selected from one of the E6 and E7 peptides as defined above, said peptides optionally being labeled or complexed, in the form of multimeric complexes.

[0123] A subject of the present invention is also a method for evaluating the immune state of an individual, characterized in that it comprises a step of detecting the presence of CD4+ T cells specific for the E6 and/or E7 peptides as defined above; said detection is advantageously carried out using one of the following assays: proliferation assay, ELISPOT assay [see, for example, international application WO 99/51630 or Gahéry-Ségard et al. (27)] or flow cytometry in the presence of multimeric complexes made up of said E6 and/or E7 peptides.

[0124] More precisely:

[0125] as regards the proliferation assay:

[0126] A suspension of cells (PBMCs, CD8+ cell-depleted PBMCs, T lymphocytes pre-enriched by a step of culturing in vitro with the peptides selected according to the invention, or cloned T lymphocytes) is cultured for 3 to 5 days in the presence of the selected peptides and, as needed, of suitable presenting cells, such as dendritic cells, autologous or heterologous PBMCs, lymphoblastoid cells such as those obtained after infection with the EBV virus or genetically modified cells. The cell proliferation is measured by incorporation of tritiated thymidine into the DNA of the cells. The peptides selected in accordance with the invention make it possible to reveal, in the initial suspension, the presence of cells specific for these peptides.

[0127] as regards the ELISPOT assay:

[0128] The ELISPOT assay makes it possible to reveal the presence of T cells specific for a peptide selected in accordance with the invention and secreting γ-IFN.

[0129] More precisely, the T cells are revealed by measuring the secretion of γ-IFN after incubation of PBMCs from patients with the peptides selected according to the invention, in accordance with the method described in Gahéry-Ségard et al., 2000 (27).

[0130] as regards the use of multimeric complexes, and in particular of tetrameric complexes:

[0131] a biological sample, preferably peripheral blood mononuclear cells (PBMCs), is brought into contact with tetrameric complexes produced from multimeric complexes made up of E6 or E7 peptides as defined above—soluble and biotinylated HLA class II molecule, and

[0132] the labeled cells are analyzed by flow cytometry.

[0133] Advantageously, prior to bringing the biological sample into contact with said complex, it is enriched in CD4+ T cells by bringing it into contact with anti-CD4 antibodies so as to enrich said sample.

[0134] The tetramers are prepared as specified, for example, in E. J. Novak et al. (J. Clin. Investig., 1999, 104, R63-R67) or in M. J. Kuroda et al. (J. Virol., 2000, 74, 18, 8751-8756).

[0135] Briefly the tetramers are produced by incubating, for 72 hours at 37° C. and in a 10 mM citrate phosphate buffer containing 0.15 M NaCl, at a pH of between 4.5 and 7, soluble and biotinylated HLA II molecules with a 10-fold excess of E6 or E7 peptides identified and selected in accordance with the invention.

[0136] The tetramerized form is obtained by adding streptavidin labeled with a fluorochrome to the preparation in an amount four times less (mole for mole) than HLA II molecules. The whole mixture is incubated overnight at ambient temperature.

[0137] To use these tetramers, a suspension of cells (PBMCs, CD8+ cell-depleted PBMCs, T lymphocytes pre-enriched by a step of culturing in vitro with the E6 or E7 peptides selected in accordance with the present invention, or cloned T lymphocytes) is brought into contact with one or more tetramers (10 to 20 mg/ml) for 1 to 3 hours. After washing, the suspension is analyzed by flow cytometry: the labeling of the cells with the tetramers is visualized by virtue of the fact that these constructs are fluorescent.

[0138] The flow cytometry makes it possible to separate the tetramer-lableled cells from the nonlabeled cells and thus to perform cell sorting.

[0139] A subject of the present invention is thus also a method for sorting HPV16-specific T lymphocytes, characterized in that it comprises at least the following steps:

[0140] incubating a suspension of cells to be sorted, or bringing it into contact, for 1 to 3 hours, with one or more tetramers formed from E6 and/or E7 peptide as defined above/soluble and biotinylated HLA II molecule complexes, and conjugated to streptavidin labeled with a fluorochrome,

[0141] analyzing by flow cytometry, and

[0142] sorting the tetramer-labeled cells.

[0143] Besides the arrangements above, the invention also comprises other arrangements which will emerge from the following description, which refers to examples of implementation of the method which is the subject of the present invention and also to the attached drawing, in which:

[0144]FIG. 1 represents the proliferation and the γ-IFN secretion of cells from a patient suffering from bowenoid papulosis and in whom the infection has been spontaneously resolved. The patient is DRB1*1601/1501 DRB5*0101. The peptide E6 (45-67) is a good ligand for DRB1*1501, and the peptide E7 (7-27) is a good ligand for DRB5*0101 (see also table VIII).

[0145] It should be clearly understood, however, that these examples are given purely by way of illustration of the subject of the invention, of which they in no way constitute a limitation.

EXAMPLE 1 Various HPV Strains and their Percentage Identity with HPV16

[0146] Strains Pathology E6 E7 HPV18 Cervical 63 40 cancer HPV31 idem 72 81 HPV33 idem 71 70 HPV45 idem 63 44 HPV58 idem 71 69 HPV30 idem 59 50 HPV34 idem 67 56 HPV35 idem 79 83 HPV39 idem 61 41 HPV40 idem 44 40 HPV42 idem 50 53 PHV43 idem 48 HPV44 idem 47 52 HPV51 idem 67 45 HPV52 idem 69 68 HPV56 idem 63 44 HPV57 idem 48 44 HPV10 warts 47 84 HPV3 idem 46 56 HPV4 idem 38 69

EXAMPLE 2 Principle of the Binding Assays

[0147] Peptide Synthesis

[0148] The peptides chosen cover the sequence of the E6 protein or of the E7 protein. All the peptides were synthesized according to the Fmoc strategy by parallel solid-phase synthesis, purified by HPLC and controlled by mass spectrometry (ES-MS).

[0149] Purification of HLA-DR Molecules

[0150] The HLA-DR molecules were purified from various homozygous EBV lines by immunoaffinity. The method described in Southwood et al. (24) can in particular be used. Their origin and the various alleles which characterize them are described in table IV. TABLE IV Other DRB Lines Specificities DRB1 alleles alleles LG2 (14) HLA-DR1 DRB1*0101 — HOM2 SCHU HLA-DR2 DRB1*1501 DRB5*0101 MAT (14) HLA-DR3 DRB1*0301 DRB3*0101 STEILIN BOLETH HLA-DR4 DRB1*0401 DRB4*0101 PREISS (14) PITOUT (14) HLA-DR7 DRB1*0701 DRB4*0101 SWEIG (14) HLA-DR11 DRB1*1101 DRB3*0202 HHKB (17) HLA-DR13 DRB1*1301 DRB3*0101

[0151] The monomorphic antibody specific for the HLA-DR molecules is in particular that described in Southwood et al. (24) or that described in Posch et al. (25). The antibodies are purified from culture supernatants on protein A-sepharose columns. These antibodies are coupled to sepharose 4B or protein A-sepharose columns for purification of the HLA-DR molecules.

[0152] HLA-DR/Peptide Binding Assays

[0153] The assays for binding of the peptides to the HLA-DR molecules are competition assays with immuno-enzymatic revelation, initially developed by Hill on the HLA-DR molecule (26). They are carried out in 96-well plates, which makes it possible to study many samples in the same experiment. Briefly, the purified HLA-DR molecules are incubated with a biotinylated peptide which serves as a tracer and various concentrations of test peptide.

[0154] After incubation for 24 to 72 hours, these samples are neutralized, and then 100 μl of each sample are transferred onto an ELISA plate precoated with the HLA-DR molecule-specific monomorphic antibody. The HLA-DR molecule/biotinylated peptide complexes, attached to the bottom of the plate via the HLA-DR molecule-specific monomorphic antibody, are revealed by means of streptavidin-phosphatase conjugate and a fluorescent substrate. The activity of each peptide is characterized by the concentration of this peptide which inhibits 50% of the binding of the biotinylated peptide (IC₅₀).

[0155] Choice and Optimization of the Binding Assays

[0156] Choice of Alleles (1st Gene)

[0157] The alleles studied are all the alleles of the French population whose frequency exceeds 5% of the population.

[0158] They are the alleles DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301 and DRB1*1501 (table I). They represent, by themselves, 53 to 82% of the alleles of Caucasian populations and make up various specificities of the HLA-DR series.

[0159] Choice of Alleles (2nd Gene)

[0160] The alleles studied are the alleles most commonly encountered. They are the alleles HLA-DRB3*0101, HLA-DRB4*0101 and HLA-DRB5*0101.

[0161] Assay Specificity

[0162] The choice of the biotinylated peptides is the determining element of the assay specificity. Most of the cells used possess two different HLA-DR molecules (encoded by two alleles) which are both purified by an HLA-DR molecule-specific monomorphic antibody and are both recognized by the same antibody. In order to unambiguously study the binding of a peptide to the DRB1 allele, it is necessary to be sure that the biotinylated peptide binds this allele and does not bind the product of the other allele.

[0163] For this purpose, the peptides as defined as reagents R1 above were used.

[0164] Assay Conditions and Sensitivity

[0165] For each HLA-DRB1 molecule, the concentration of MHC II molecules, the concentration of the biotinylated peptide, the incubation pH and the incubation time were optimized as specified in table V below. TABLE V Protein Tracer concen- concen- Incubation tration tration Optimum time Alleles (μg/ml) Tracers (nM) pH (h) DRB1*0101 0.6 HA 306-318 10 6 24 DRB1*0301 2.3 MT 2-16 50 4.5 72 DRB1*0401 1.6 HA 306-318 30 6 24 DRB1*0701 0.4 YKL 10 5 24 DRB1*1101 1.3 HA 306-318 20 5 24 DRB1*1301 0.7 B1 21-36 200 4.5 72 DRB1*1501 0.5 A3 152-166 10 4.5 24

[0166] The sensitivity of each assay is reflected by the IC₅₀ values observed with the nonbiotinylated peptides which correspond to the tracers, and the results obtained are given in table VI below. TABLE VI Biotinylated Alleles Frequency peptides Sequences IC₅₀ (Nm) DRB1*0101 9.3 HA 306-318 PKYVKQNTLKLAT 31 DRB1*0401 5.6 HA 306-318 PKYVKQNTLKLAT 44 DRB1*1101 9.2 HA 306-318 PKYVKQNTLKLAT 38 DRB1*0701 14.0 YKL AAYAAAKAAALAA 34 DRB1*0301 10.9 MT 2-16 AKTIAYDEEARRGLE 100 DRB1*1301 6.0 B1 21-36 TERVRLVTRHIYNREE 330 DRB1*1501 8.0 A3 152-166 EAEQLRRAYLDGTGVE 14 DRB5*0101 7.9 HA 306-318 PKYVKQNTLKLAT 6.5 DRB3*0101 9.2 Lol 191-210 ESWGAVWRIDTPDKLTGPFT 5 DRB4*0101 28.4 E2/E168 AGDLLAIETDKATI 2

[0167] The frequencies indicated are the allelic frequencies in France and are representative of those of the Caucasian population. They are derived from Colombani (22).

[0168] Tables VIIa and VIIb below illustrate the binding activity of the peptides according to the invention, measured under the conditions specified above. TABLE VIIa Binding activities of the selected E6 and E7 peptides with respect to the HLA-DR molecules which are predominant in the Caucasian population DR1 DR3 DR4 DR7 DR11 DR13 DR15 B3 B5 B4 E6/1 >10000 3500 >10000 >10000 >10000 >10000 >10000 10000 >10000 >10000 (1-22) E6/2 3500 550 >10000 225 10000 >10000 800 1450 >10000 >10000 (14-34) E6/3 400 1000 450 1400 800 250 75 1500 3.5 700 (30-50) E6/4 50 >10000 2000 2330 125 >10000 225 2500 65 >10000 (45-67) E6/5 1750 100 2500 10000 60 >10000 400 200 9.5 6500 (61-80) E6/6 3.5 >10000 5000 3500 150 300 24 >10000 120 27 (76-95) E6/7 30 200 90 500 2000 >10000 5.5 9500 50 6500 (91-110) E6/8 1750 >10000 3750 >10000 5000 5000 4000 >10000 30 70 (105-126) E6/9 125 >10000 >10000 200 350 1130 >10000 >10000 85 >10000 (121-140) E6/10 200 >10000 17.5 10000 700 >10000 1600 >10000 10 4250 (135-158) E7/I 2500 >10000 300 >10000 1750 >10000 125 35 >10000 4 (1-20) E7/II 300 560 60 >10000 600 7500 1770 8.5 70 375 (7-27) E7/III >10000 4600 1750 >10000 >10000 >10000 5300 >10000 >10000 >10000 (21-40) E7/IV >10000 >10000 >10000 >10000 >10000 >10000 >10000 >10000 >10000 >10000 (35-55) E7/V >10000 >10000 >10000 >10000 >10000 >10000 2000 >10000 2250 >10000 (43-57) E7/VI 5000 >10000 2000 900 7000 >10000 >10000 >10000 200 1950 (60-74) E7/VII 650 450 650 900 2000 >10000 470 850 2000 2000 (65-87) E7/VIII 800 >10000 2250 500 900 >10000 35 >10000 350 500 (78-98)

[0169] TABLE VIIb Binding activities of the selected E6 and E7 peptides with respect to the HLA-DR molecules which are predominant in a Caucasian population SEQ ID peptide No. e DR1 DR3 DR4 DR7 DR11 DR13 DR15 DRB3 DRB4 DRB5 E6/2 (14-34) No. 8 E6 17-31 No. 20 10000 6500 1750 E6 20-34 No. 21 45 >10000 >10000 7000 >10000 E6 24-38 No. 22 425 300 >10000 1500 300 >10000 950 >10000 >10000 E6 28-42 No. 23 45 >10000 1200 >10000 2000 >10000 450 4250 50 E6/3 (30-50) No. 10 E6 31-45 No. 24 65 >10000 2250 600 10000 750 >10000 95 E6 36-50 No. 25 38 2750 5000 525 >10000 225 >10000 15 E6/4 (45-67) No. 26 E6 42-56 No. 28 >10000 >10000 >10000 6000 375 3250 55 >10000 E6 50-64 No. 29 900 85 6500 1483 60 E6 55-69 No. 30 1500 250 55 >10000 E6/6 (76-95 No. 12 E6 76-90 No. 31 125 525 225 500 >10000 1050 E6 78-92 No. 32 225 1750 2250 120 >10000 1250 E6 81-95 No. 33 10 725 >10000 >10000 >10000 2500 E6 84-98 No. 34 2000 3250 7000 >10000 >10000 >10000 900 E6/7 (91-110) No. 35 E6 89-103 No. 36 125 5000 1500 >10000 >10000 53 >10000 200 E6 93-107 No. 37 5 >10000 7750 18 325 E6 97-111 No. 38 575 1233 325 >10000 4000 5500 E6 101-115 No. 39 12 3000 25 350 150 5 E6/9 (121-140) No. 41 E6 124-138 No. 42 10 >10000 475 75 E6 130-144 No. 43 4 950 115 75 E7/1 (1-20) No. 14 E7 6-20 No. 45 750 >10000 175 1500 675 90 200 2000 E7/2 (7-27) No. 15 E7 9-23 No. 46 325 >10000 375 9500 65 >10000 >10000 E7 13-27 No. 47 4000 3500 4250 3500 10000 >10000 >10000 E7/7 (65-87) No. 17 E7 65-79 No. 48 750 >10000 >10000 600 >10000 >10000 E7 67-81 No. 49 7000 >10000 7500 1500 950 >10000 E7 72-86 No. 50 25 900 100 2000 35 600 E7/8 (78-98) No. 18 E7 77-91 No. 51 5 55 >10000 >10000 700 E7 84-98 No. 52 20 1250 425 1750 90

[0170] The results are expressed in the form of concentrations giving 50% inhibition of maximum binding. The unit is nM.

EXAMPLE 3 Proliferation Assay

[0171] To verify the stimulation of CD4+ T cell proliferation using immunogenic composition according to the invention, a proliferation assay is performed in vitro.

[0172] The cells (PBMCs) extracted from peripheral blood were cultured in 96-well microplates in a proportion of 2×10⁵ cells per well, in a final volume of 200 μl of complete medium. The cells were or were not stimulated with 10 μg/ml of a mixture of peptides according to the invention. After culturing for 5 days at 37° C., the cells were incubated overnight with 0.25 μCi of [³H]-thymidine (Amersham, Life technology). The cells were recovered and the [³H]-thymidine incorporation was measured in a cellular DNA.

[0173] Stimulation of the CD4+ T cells is effectively observed.

[0174] Other cells can be used: CD8+ cell-depleted PBMCs, T cells pre-enriched by a step of culturing in vitro with the peptides as defined above, or cloned lymphocytes.

[0175] Briefly, the enriching protocol is as follows:

[0176] The PBMCs, separated on a Ficoll gradient, are cultured at 37° C. in the presence of 0.1 to 10 mg/ml of peptides in RPMI medium supplemented with 10% human serum. On the 7th and 11th day of culturing, 50 units of recombinant human IL-2 are added to the culture. The cells are harvested on the 14th day.

EXAMPLE 4 Elispot

[0177] The ELISPOT makes it possible to detect cells which are specific for a peptide and which secrete a given cytokine.

[0178] 50 μl/well of murine anti-human γ-IFN antibody diluted, in PBS buffer, to a concentration of 4 μg/ml are incubated in nitrocellulose-bottomed 96-well plates overnight at 4° C. in a humid chamber.

[0179] The wells are washed with PBS and saturated with RPMI medium containing 10% calf serum for 2 hours at 37° C.

[0180] If needed, suitable presenting cells, such as autologous or heterologous PBMCs, lymphoblastoid cells obtained after infection with the EBV virus or genetically modified cells, are used and are dispensed into the wells. The E6 or E7 peptides as defined in the invention are then added at various concentrations (10, 5 and 1 μg/ml).

[0181] The effector cells (PBMCs, CD8+ cell-depleted PBMCs, T lymphocytes pre-enriched by a step of culturing in vitro with the E6 or E7 peptides or both, or cloned lymphocytes) are added to the 96-well plates in a proportion of 20 000 cells/well.

[0182] The culture is incubated for 24 hours at 37° C. in an atmosphere containing 5% CO₂.

[0183] The plates are then washed and incubated for 2 hours with 100 μl of a rabbit antiserum specific for human γ-IFN.

[0184] After washing, an anti-rabbit IgG antibody conjugated to biotin then streptavidin conjugated to alkaline phosphatase are added successively for 1 hour.

[0185] Finally, the spots are revealed by virtue of a chromogenic substrate of alkaline phosphatase. These spots are counted under a microscope. Negative controls are given by the wells containing no peptides. The positive controls are provided by the wells containing mitogenic agents such as ionomycin (500 ng/ml) and phytohemagglutinin (PHA) (10 μg/ml).

EXAMPLE 5 In vivo Assay

[0186] The mixtures of peptides as defined above were assayed in vivo, in patients having bowenoid papulosis. Bowenoid papulosis is a cutaneous-mucosal infection due to HPV16 which affects young women; it is a chronic and recurring disease, despite the destructive treatments used. This disease is a vulvar intraepithelial neoplasm grade 3 from the beginning (VIN 3), which has the particularity of not progressing to an invasive carcinoma.

[0187] The considerable infiltration of the epithelium by numerous CD4+ lymphocytes suggests that these cells contribute to controlling the stage of the disease and to preventing invasion.

[0188] The results observed in a patient who had resolved the infection herself are given by way of example in FIG. 1.

[0189] The proliferative response of the cells from 13 patients having bowenoid papulosis, with respect to the peptides, was studied.

[0190] The peptides recognized, in terms of proliferation, by the CD4+ T lymphocytes were listed for each disease.

[0191] The results obtained are given in table VIII below.

[0192] This table shows the advantage of the peptides selected in accordance with the present invention. TABLE VIII Possible Reminder Possible Reminder Patients 1st DR 2nd DR 1st DR 2nd DR Prolif DR IC₅₀ ELISPOT DR IC₅₀ GUI 1601 (?) DRB5 1501 (?) DRB5 E6/2 1501    800 E6/4 1501    225 DRB5 >10 000 DRB5    65 E6/4 1501    225 E7/2 1501  1 770 DRB5    65 DRB5    70 E7/3 1501  5 300 DRB5 >10 000 CAR 701 (?) DRB4 E6/2  701    225 DRB4 >10 000 E7/2  701 >10 000 DRB4    375 JOU 1501 (?) DRB5 E6/2 1501    800 DRB5 >10 000 E6/4 1501    225 DRB5    65 E6/5 1501    400 DRB5      9.5 E6/10 1501  1 600 DRB5    10 E7/2 1501  1 770 DRB5    70 RIZ 1501 (?) DRB5 0404 or 0101 423 weak 1501    400 E6/5 DRB5      9.5 weak 1501  1 600 E6/10 DRB5    10 ROU 411 (?) DRB4 701 (?) DRB4 weak ALB 1301 (?) DRB3 1101 (?) uninterpretable LOK 1501 (?) DRB5 801 negative ALC 311 (?) DRB3 1501 (?) E6/2 1501    800 E6/2 1501    800 DRB5 >10 000 DRB5 >10 000 E6/4 1501    225 E6/4 1501    225 DRB5    65 E6/5 1501    400 DRB5      9.5 E6/7 1501      5.5 DRB5    50 E6/8 1501  4 000 DRB5    30 E7/2 1501  1 770 DRB5    70 E7/3 1501  5 300 DRB5 >10 000 E7/4 1501 >10 000 DRB5 >10 000 E7/7 1501    470 DRB5  2 000 E7/8 1501    35 DRB5    350 BRO 1101 (?) DRB3 1001 E6/2 1101  10 000 DRB3  1 450 E6/4 1101    125 DRB3  2 500 BLAI 1101 (?) DRB3 701 (?) DRB4 E6/2 1101  10 000 (?) DRB3  1 450  701    225 (?) DRB4 >10 000 E6/4 1101    125 (?) DRB3  2 500  701  2 330 (?) DRB4 >10 000 LEG 1501 (?) DRB5 801 (?) E6/2 1501    800 DRB5 >10 000 E6/7 1501      5.5 DRB5    60 E7/7 1501    470 DRB5  2 000 E6/10 1501  1 600 DRB5    10 CAI 701 (?) DRB4 1501 (?) DRB5 E6/2 1501    800 DRB5 >10 000  701    225 DRB4 >10 000 E6/4 1501    225 DRB5    65  701  2 330 DRB4 >10 000 DEL 701 (?) DRB4 E6/2  701    225 E6/2  701    225 DRB4 >10 000 DRB4 >10 000 E6/4  701  2 330 E6/4  701  2 330 DRB4 >10 000 DRB4 >10 000

BIBLIOGRAPHICAL REFERENCES

[0193] 1. Lowy D. R. et al., Proc. Natl. Acad. Sci. USA, 1994, 91, 2436.

[0194] 2. Borysiewicz L. K. et al., Lancet, 1996, 347, 1523.

[0195] 3. Ressing M. E. et al., J. Immunother., 2000, 23, 255.

[0196] 4. Van Driel W. J. et al., Eur. J. Cancer, 1999, 35, 946.

[0197] 5. Ridge J. P., Nature, 1998, 393, 474.

[0198] 6. Schoenberger S. P. et al., Nature, 1998, 393, 480.

[0199] 7. Bennett S. R. et al., Nature, 1998, 393, 478.

[0200] 8. Toes R. E. M. et al., Semin. Immunol., 1998, 10, 443.

[0201] 9. Tindle R. W. et al., Proc. Natl. Acad. Sci. USA, 1991, 88, 5887.

[0202] 10. Azoury-Ziadeh R. K. et al., Viral. Immunol., 1999, 12, 297.

[0203] 11. Hohn H. et al., J. Immunol., 1999, 163, 5715.

[0204] 12. Hohn H. et al., J. Virol., 2000, 74, 6632.

[0205] 13. Bontkes H. J. et al., J. Gen. Virol., 1999, 80, 409.

[0206] 14. Strang G. et al., J. Gen. Virol., 1990, 71, 423.

[0207] 15. Altmann A. et al., Eur. J. Cancer, 1992, 28, 326.

[0208] 16. Luxton J. C. et al., J. Gen. Virol., 1996, 77, 1585.

[0209] 17. Tsukui T. et al., Cancer Res., 1996, 56, 3967.

[0210] 18. Nakagawa M. et al., Clin. Diagn. Lab. Immunol., 1996, 3, 205.

[0211] 19. Kadish A. S. et al., J. Natl. Cancer Inst., 1997, 89, 1285.

[0212] 20. de Gruijl T. D. et al., Cancer Res., 1998, 58, 1700.

[0213] 21. Doan T. et al., J. Virol., 1999, 74, 6166.

[0214] 22. Colombani J., 1993, HLA: fonctions immunitaires et applications médicales, Eds. John Libbey Eurotext.

[0215] 23. Ressing M. E. et al., J. Immunol., 1995, 154, 5934.

[0216] 24. Southwood et al., J. Immunol., 1998, 160, 3363-3373.

[0217] 25. Posch et al., Eur. J. Immunol., 1996, 26, 1884.

[0218] 26. Hill et al., J. Immunol., 1994, 152, 2890.

[0219] 27. Gahéry-Ségard et al., J. Virol., 2000, 74, 1694.

1 63 1 13 PRT artificial sequence Description of the artificial sequence peptide HA 306-318 1 Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr 1 5 10 2 15 PRT artificial sequence Description of the artificial sequence peptide A3 152-166 2 Glu Ala Glu Gln Leu Arg Ala Tyr Leu Asp Gly Thr Gly Val Glu 1 5 10 15 3 14 PRT artificial sequence Description of the artificial sequence peptide MT 2-16 3 Ala Lys Thr Ile Ala Tyr Asp Glu Glu Ala Arg Gly Leu Glu 1 5 10 4 13 PRT artificial sequence Description of the artificial sequence peptide YKL 4 Ala Ala Tyr Ala Ala Ala Lys Ala Ala Ala Leu Ala Ala 1 5 10 5 16 PRT artificial sequence Description of the artificial sequence peptide B1 21-36 5 Thr Glu Arg Val Arg Leu Val Thr Arg His Ile Tyr Asn Arg Glu Glu 1 5 10 15 6 20 PRT artificial sequence Description of the artificial sequence peptide LOL 191-210 6 Glu Ser Trp Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr 1 5 10 15 Gly Pro Phe Thr 20 7 14 PRT artificial sequence Description of the artificial sequence peptide E2/E168 7 Ala Gly Asp Leu Leu Ala Ile Glu Thr Asp Lys Ala Thr Ile 1 5 10 8 21 PRT artificial sequence Description of the artificial sequence peptide E6 14-34 8 Glu Arg Pro Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr 1 5 10 15 Ile His Asp Ile Ile 20 9 32 PRT artificial sequence Description of the artificial sequence peptide E6 14-45 9 Glu Arg Pro Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr 1 5 10 15 Ile His Asp Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu 20 25 30 10 21 PRT artificial sequence Description of the artificial sequence peptide E6 30-50 10 Ile His Asp Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu 1 5 10 15 Arg Arg Glu Val Tyr 20 11 20 PRT artificial sequence Description of the artificial sequence peptide E6 61-80 11 Tyr Arg Asp Gly Asn Pro Tyr Ala Val Cys Asp Lys Cys Leu Lys Phe 1 5 10 15 Tyr Ser Lys Ile 20 12 20 PRT artificial sequence Description of the artificial sequence peptide E6 76-95 12 Phe Tyr Ser Lys Ile Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr 1 5 10 15 Gly Thr Thr Leu 20 13 29 PRT artificial sequence Description of the artificial sequence peptide E6 91-119 13 Tyr Gly Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu 1 5 10 15 Leu Ile Arg Cys Ile Asn Cys Gln Lys Pro Leu Cys Pro 20 25 14 20 PRT artificial sequence Description of the artificial sequence peptide E7 1-20 14 Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln 1 5 10 15 Pro Glu Thr Thr 20 15 21 PRT artificial sequence Description of the artificial sequence peptide E7 7-27 15 Thr Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu 1 5 10 15 Tyr Cys Tyr Glu Gln 20 16 15 PRT artificial sequence Description of the artificial sequence peptide E7 60-74 16 Lys Cys Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr His Val 1 5 10 15 17 23 PRT artificial sequence Description of the artificial sequence peptide E7 65-87 17 Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu 1 5 10 15 Asp Leu Leu Met Gly Thr Leu 20 18 21 PRT artificial sequence Description of the artificial sequence peptide E7 78-98 18 Thr Leu Glu Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile 1 5 10 15 Cys Ser Gln Lys Pro 20 19 33 PRT artificial sequence Description of the artificial sequence peptide E6 14-46 19 Glu Arg Pro Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr 1 5 10 15 Ile His Asp Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu 20 25 30 Arg 20 15 PRT artificial sequence Description of the artificial sequence peptide E6 17-31 20 Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile His 1 5 10 15 21 15 PRT artificial sequence Description of the artificial sequence peptide E6 20-34 21 Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile His Asp Ile Ile 1 5 10 15 22 15 PRT artificial sequence Description of the artificial sequence peptide E6 24-38 22 Thr Glu Leu Gln Thr Thr Ile His Asp Ile Ile Leu Glu Cys Val 1 5 10 15 23 15 PRT artificial sequence Description of the artificial sequence peptide E6 28-42 23 Thr Thr Ile His Asp Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln 1 5 10 15 24 15 PRT artificial sequence Description of the artificial sequence peptide E6 31-45 24 His Asp Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu 1 5 10 15 25 15 PRT artificial sequence Description of the artificial sequence peptide E6 36-50 25 Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr 1 5 10 15 26 22 PRT artificial sequence Description of the artificial sequence peptide E6 45-67 26 Leu Arg Arg Glu Val Tyr Asp Phe Ala Arg Asp Leu Cys Ile Val Tyr 1 5 10 15 Arg Asp Gly Asn Pro Tyr 20 27 23 PRT artificial sequence Description of the artificial sequence peptide E6 44-67 27 Leu Leu Arg Arg Glu Val Tyr Asp Phe Ala Arg Asp Leu Cys Ile Val 1 5 10 15 Tyr Arg Asp Gly Asn Pro Tyr 20 28 15 PRT artificial sequence Description of the artificial sequence peptide E6 42-56 28 Gln Gln Leu Leu Arg Arg Glu Val Tyr Asp Phe Ala Phe Arg Asp 1 5 10 15 29 15 PRT artificial sequence Description of the artificial sequence peptide E6 50-64 29 Tyr Asp Phe Ala Phe Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly 1 5 10 15 30 15 PRT artificial sequence Description of the artificial sequence peptide E6 55-69 30 Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly Asn Pro Tyr Ala Val 1 5 10 15 31 15 PRT artificial sequence Description of the artificial sequence peptide E6 76-90 31 Phe Tyr Ser Lys Ile Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu 1 5 10 15 32 15 PRT artificial sequence Description of the artificial sequence peptide E6 78-92 32 Ser Lys Ile Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly 1 5 10 15 33 15 PRT artificial sequence Description of the artificial sequence peptide E6 81-95 33 Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu 1 5 10 15 34 15 PRT artificial sequence Description of the artificial sequence peptide E6 84-98 34 Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln 1 5 10 15 35 20 PRT artificial sequence Description of the artificial sequence peptide E6 91-110 35 Tyr Gly Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu 1 5 10 15 Leu Ile Arg Cys 20 36 15 PRT artificial sequence Description of the artificial sequence peptide E6 89-103 36 Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro Leu 1 5 10 15 37 15 PRT artificial sequence Description of the artificial sequence peptide E6 93-107 37 Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu 1 5 10 15 38 15 PRT artificial sequence Description of the artificial sequence peptide E6 97-111 38 Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile 1 5 10 15 39 15 PRT artificial sequence Description of the artificial sequence peptide E6 101-115 39 Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile Asn Cys Gln Lys 1 5 10 15 40 23 PRT artificial sequence Description of the artificial sequence peptide E6 118-140 40 Cys Pro Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg Phe His 1 5 10 15 Asn Ile Arg Gly Arg Trp Thr 20 41 20 PRT artificial sequence Description of the artificial sequence peptide E6 121-140 41 Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg Phe His Asn Ile Arg 1 5 10 15 Gly Arg Trp Thr 20 42 14 PRT artificial sequence Description of the artificial sequence peptide E6 124-138 42 His Leu Asp Lys Lys Gln Arg Phe His Asn Ile Arg Gly Arg 1 5 10 43 15 PRT artificial sequence Description of the artificial sequence peptide E6 130-144 43 Gln Arg Phe His Asn Ile Arg Gly Arg Trp Thr Gly Arg Cys Met 1 5 10 15 44 24 PRT artificial sequence Description of the artificial sequence peptide E6 135-158 44 Ile Arg Gly Arg Trp Thr Gly Arg Cys Met Ser Cys Cys Arg Ser Ser 1 5 10 15 Arg Thr Arg Arg Glu Thr Gln Leu 20 45 15 PRT artificial sequence Description of the artificial sequence peptide E7 6-20 45 Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr 1 5 10 15 46 15 PRT artificial sequence Description of the artificial sequence peptide E7 9-23 46 His Glu Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu Tyr 1 5 10 15 47 15 PRT artificial sequence Description of the artificial sequence peptide E7 13-27 47 Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln 1 5 10 15 48 15 PRT artificial sequence Description of the artificial sequence peptide E7 65-79 48 Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu 1 5 10 15 49 15 PRT artificial sequence Description of the artificial sequence peptide E7 67-81 49 Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu Asp 1 5 10 15 50 15 PRT artificial sequence Description of the artificial sequence peptide E7 72-86 50 Thr His Val Asp Ile Arg Thr Leu Glu Asp Leu Leu Met Gly Thr 1 5 10 15 51 15 PRT artificial sequence Description of the artificial sequence peptide E7 77-91 51 Arg Thr Leu Glu Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys 1 5 10 15 52 15 PRT artificial sequence Description of the artificial sequence peptide E7 84-98 52 Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln Lys Pro 1 5 10 15 53 30 PRT artificial sequence Description of the artificial sequence peptide E6 15-44 53 Arg Pro Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile 1 5 10 15 His Asp Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu 20 25 30 54 21 PRT artificial sequence Description of the artificial sequence peptide E6 46-67 54 Arg Arg Glu Val Tyr Asp Phe Ala Arg Asp Leu Cys Ile Val Tyr Arg 1 5 10 15 Asp Gly Asn Pro Tyr 20 55 29 PRT artificial sequence Description of the artificial sequence peptide E6 80-108 55 Ile Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu 1 5 10 15 Glu Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile 20 25 56 22 PRT artificial sequence Description of the artificial sequence peptide E6 118-139 56 Cys Pro Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg Phe His 1 5 10 15 Asn Ile Arg Gly Arg Trp 20 57 23 PRT artificial sequence Description of the artificial sequence peptide E7 3-25 57 Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu 1 5 10 15 Thr Thr Asp Leu Tyr Cys Tyr 20 58 19 PRT artificial sequence Description of the artificial sequence peptide E7 79-97 58 Leu Glu Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys 1 5 10 15 Ser Gln Lys 59 22 PRT artificial sequence Description of the artificial sequence peptide E6 1-22 59 Met His Gln Lys Arg Thr Ala Met Phe Gln Asp Pro Gln Glu Arg Pro 1 5 10 15 Arg Lys Leu Pro Gln Leu 20 60 22 PRT artificial sequence Description of the artificial sequence peptide E6 105-126 60 Asp Leu Leu Ile Arg Cys Ile Asn Cys Gln Lys Pro Leu Cys Pro Glu 1 5 10 15 Glu Lys Gln Arg His Leu 20 61 20 PRT artificial sequence Description of the artificial sequence peptide E7 21-40 61 Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser Glu Glu Glu Asp 1 5 10 15 Glu Ile Asp Gly 20 62 21 PRT artificial sequence Description of the artificial sequence peptide E7 35-55 62 Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp Arg Ala 1 5 10 15 His Tyr Asn Ile Val 20 63 15 PRT artificial sequence Description of the artificial sequence peptide E7 43-57 63 Gly Gln Ala Glu Pro Asp Arg Ala His Tyr Asn Ile Val Thr Phe 1 5 10 15 

1. A mixture of peptides derived from an E6 protein and/or from an E7 protein of an HPV involved in cervical cancer or benign lesions of the skin, characterized in that each of the peptides included in said mixture binds to at least one HLA-DRB1 (1st gene) molecule the frequency of which is greater than 5% in the Caucasian population and, optionally, to at least one HLA-DRB3, HLA-DRB4 or HLA-DRB5 (2nd gene) molecule, with a binding activity <1 000 nM, preferably <800 nM, said mixture of peptides binding to at least eight HLA class II molecules, the frequency of which is greater than 5% in the Caucasian population, encoded by the alleles selected from the group consisting of the alleles HLA DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301 and DRB1*1501 (DR1, DR3, DR4, DR7, DR11, DR13 and DR15 molecules) (1st gene) and the alleles DRB3*0101, DRB4*0101 and DRB5*0101 (B3, B4 and B5) (2nd gene).
 2. The mixture of peptides according to claim 1, characterized in that the peptides derived from an E6 protein of HPV are derived from HPV16 and are selected from the group consisting of: (a) a peptide included between positions 14 and 16, selected from the group consisting of the peptide corresponding to positions 14-34 and the peptide corresponding to positions 14-46 (SEQ ID Nos. 8, 19), (b) the peptide corresponding to positions 30-50 (SEQ ID No. 10), (c) a peptide included between positions 44 and 67, selected from the group consisting of the peptide corresponding to positions 45-67 and the peptide corresponding to positions 44-67 (SEQ ID Nos. 26, 27), (d) the peptide corresponding to positions 61-80 (SEQ ID No. 11), (e) a peptide included between positions 76 and 119, selected from the group consisting of the peptide corresponding to positions 76-95, the peptide corresponding to positions 91-110 and the peptide corresponding to positions 91-119 (SEQ ID Nos. 12, 35, 13), (f) a peptide included between positions 118-140, selected from the group consisting of the peptide corresponding to positions 118-140 and the peptide corresponding to positions 121-140 (SEQ ID Nos. 40, 41), (g) the peptide corresponding to positions 135-158 (SEQ ID No. 44), of the E6 protein of HPV16, and (h) the peptides, preferably of 15 to 20 amino acids, exhibiting an amino acid sequence having at least 60% identity or at least 80% similarity, and preferably at least 70% identity or at least 99% similarity, with the peptides defined in (a)-(g), said peptides being identical in size, included in the peptides defined in (a)-(g) or else completely or partially overlapping these peptides, with the exclusion of the peptides corresponding to positions 15-44, 46-67, 80-108 and 118-139 of the E6 protein of HPV16 (SEQ ID Nos. 53-56).
 3. The mixture of peptides according to claim 1 or claim 2, characterized in that the peptides derived from an E7 protein are derived from HPV16 and are selected from the group consisting of the peptide corresponding to positions 1-20, the peptide corresponding to positions 7-27, the peptide corresponding to positions 65-87 and the peptide corresponding to positions 78-98 of said E7 protein of HPV16 and the peptides, preferably of 15 to 20 amino acids, exhibiting an amino acid sequence having at least 60% identity or at least 80% similarity, and preferably at least 70% identity or at least 99% similarity, with the above peptides, said peptides being identical in size, or included in the above peptides or else overlapping these peptides, with the exclusion of the peptides corresponding to positions 3-25 and 79-97 of the E7 protein of HPV16 (SEQ ID Nos. 57, 58).
 4. The mixture of peptides according to any one of claims 1 to 3, characterized in that it is selected from the group consisting of the following mixtures: a mixture of peptides derived from the E6 protein of HPV16, comprising: the peptide corresponding to positions 14-34 or to positions 14-46, the peptide corresponding to positions 30-50 and the peptide corresponding to positions 44-67 or to positions 45-67; a mixture of peptides derived from the E6 protein of HPV16, comprising: the peptide corresponding to positions 61-80, the peptide corresponding to positions 76-95 and the peptide corresponding to positions 91-119; a mixture of peptides derived from the E7 protein of HPV16, comprising: the peptide corresponding to positions 1-20 and the peptide corresponding to positions 7-27; a mixture of peptides derived from the E7 protein of HPV16, comprising: the peptide corresponding to positions 65-87 and the peptide corresponding to positions 78-98; and the mixtures comprising one of the mixtures of peptides derived from the E6 protein HPV16 and one of the mixtures derived from the E7 protein of HPV16.
 5. An immunogenic anti-HPV16 composition, characterized in that it comprises a mixture of peptides derived from an E6 protein of HPV and/or a mixture of peptides derived from an E7 protein of HPV, according to any one of claims 1 to 4, combined with at least one pharmaceutically acceptable vehicle and, optionally, with at least one adjuvant.
 6. The composition according to claim 5, characterized in that said peptides are either in the form of lipopeptides, or incorporated into a recombinant virus or a viral vector for gene therapy, or included in a protein, or chemically modified.
 7. The composition according to claim 5 or claim 6, characterized in that said mixture of peptides is combined: with one or more peptides or lipopeptides containing one or more CD8+ epitopes, and more particularly the CD8+ epitopes derived from an HPV protein, in particular from an HPV16 protein, and/or with other peptides comprising multiple CD4+ epitopes, such as the tetanus toxin TT peptide (positions 830-846), the Influenza hemagglutinin HA peptide (positions 307-319), PADRE and the Plasmodium falciparum LSA3 peptide, and/or with one or more peptides or lipopeptides containing one or more B epitopes, more particularly B epitopes derived from an HPV16 protein.
 8. An immunogenic composition, characterized in that it advantageously comprises the sequences encoding the peptides as defined in claims 1 to
 4. 9. A vaccine, characterized in that it includes an immunogenic composition according to any one of claims 5 to
 8. 10. A peptide derived from an E6 protein of HPV, in particular of HPV16, and/or from an E7 protein of HPV, in particular of HPV16, characterized: in that it contains a CD4+ epitope capable of having a binding activity <1 000 nM, preferably <800 nM, with respect to at least one HLA II (HLA-DR) molecule predominant in Caucasian populations (1st gene and/or 2nd gene), as defined in claims 1 to 6, of being recognized by CD4+ T lymphocytes specific for said peptides, and of stimulating CD4+ T lymphocytes specific for said peptides, and in that it is selected from the group consisting of the fragments of sequence SEQ ID Nos. 8 to 18, 21-25, 28-34, 36-39, 42-43 and 45-52, corresponding respectively to the following peptides of the E6 protein of HPV16: the peptide E6 (14-34 or 14-45), the peptide E6 (30-50), the peptide E6 (61-80), the peptide E6 (76-95), the peptide E6 (91-119) and the peptides E6 (20-34, 24-38, 28-42, 31-45, 36-50, 42-56, 50-64, 55-69, 76-90, 78-92, 81-95, 84-98, 89-103, 93-107, 97-111, 101-115, 124-138, 130-144), or to the following peptides of the E7 protein of HPV16: the peptide E7 (1-20), the peptide E7 (7-27), the peptide E7 (60-74), the peptide E7 (65-87), the peptide E7 (78-98) and the peptides E7 (6-20, 9-23, 13-27, 65-79, 67-81, 72-86, 77-91, 84-98).
 11. A diagnostic reagent, characterized in that it is selected from the group consisting of the peptides as defined in claims 1 to 4 or the peptides as claimed in claim 10, said peptides optionally being labeled or complexed, in the form of multimeric complexes.
 12. A method for evaluating the immune state of an individual, characterized in that it comprises a step of detecting the presence of CD4+ T cells specific for the E6 and/or E7 peptides as defined in claims 1 to 4, using an ELISPOT assay, a T cell proliferation assay or an assay using multimeric complexes.
 13. A method for sorting HPV16-specific T lymphocytes, characterized in that it comprises at least the following steps: incubating a suspension of cells to be sorted, or bringing it into contact, for 1 to 3 hours, with one or more tetramers formed from multimeric complexes made up of the E6 and/or E7 peptides as defined in claims 1 to 4 and 10/soluble and biotinylated HLA II molecule, and conjugated to streptavidin labeled with a fluorochrome, analyzing by flow cytometry, and sorting the tetramer-labeled cells.
 14. The mixture of peptides according to claim 2, characterized in that said peptides as defined in h) are selected from the group consisting of the peptides corresponding respectively to positions 20-34, 24-38, 28-42, 31-45, 36-50, 42-56, 50-64, 55-69, 76-90, 78-92, 81-95, 84-98, 89-103, 93-107, 97-111, 101-115, 124-138 and 130-144 of the E6 protein of HPV16 (SEQ ID Nos. 21-25, 28-34, 36-39, 42-43).
 15. The mixture of peptides according to claim 3, characterized in that said peptides are selected from the group consisting of the peptides corresponding respectively to positions 6-20, 9-23, 13-27, 65-79, 67-81, 72-86, 77-91 and 84-98 of the E7 protein of HPV16 (SEQ ID Nos. 45-52). 